Immuneering Corp IMRX
Immuneering Corp (Nasdaq: IMRX) is an oncology drug developer. Its lead program, atebimetinib (IMM-1-104), is in Phase 3 for first-line metastatic pancreatic ductal adenocarcinoma (PDAC). Its next catalyst on record is atebimetinib + Libtayo: Dose first patient in clinical trial (NSCLC) (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: atebimetinib + Libtayo — Dose first patient in clinical trial (NSCLC) (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| atebimetinib (IMM-1-104) + mGnP | first-line metastatic pancreatic cancer | small molecule | Phase 3 |
| atebimetinib (IMM-1-104) Phase 2a | first-line pancreatic cancer + mGnP | small molecule | Phase 2 |
| atebimetinib (IMM-1-104) + Libtayo | non-small cell lung cancer | small molecule | Phase 1 |
| envometinib (IMM-6-415) | advanced solid tumors (de-prioritized) | small molecule | Phase 1 |
| Next DCI product candidate program | not disclosed | small molecule | Pre-clinical |
Recent results and decisions
- Jun 30, 2026started Phase 3 MAPKeeper 301 trial of atebimetinib plus chemotherapy in first-line pancreatic cancer has dosed first patient.
In June, Immuneering announced it had dosed the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer patients.
Filing - Jun 1, 2026positive Atebimetinib plus mGnP demonstrated 17.3 month median overall survival in 55 first-line pancreatic cancer patients in Phase 2a trial, presented at ASCO.
17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1
Filing - Jun 1, 2026started MAPKeeper 301 pivotal Phase 3 trial of atebimetinib plus mGnP in first-line metastatic pancreatic cancer has dosed its first patient.
In June, Immuneering announced it had dosed the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer patients.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.